What is NDC 0832-1075?

0832-1075 is the product NDC for Topiramate, Topiramate 150 mg/1 capsule, extended release, listed with the FDA by Upsher-Smith Laboratories, LLC. It has 3 package NDCs, shown above in 10- and 11-digit form.

Upsher-Smith Laboratories, LLC, NDC labeler code 0832. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Topiramate?

276 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Topiramate NDC 0832-1075 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)0832-1075Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00832-1075Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
0832-1075-15	00832107515	500 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0832-1075-15)Marketed from Jul 7, 2014
0832-1075-30	00832107530	1 BOTTLE in 1 CARTON (0832-1075-30) / 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLEMarketed from Jul 7, 2014
0832-1075-90	00832107590	1 BOTTLE in 1 CARTON (0832-1075-90) / 90 CAPSULE, EXTENDED RELEASE in 1 BOTTLEMarketed from Jul 7, 2014

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Topiramate
Generic name (nonproprietary): topiramate
Active ingredients: Topiramate — 150 mg/1
Dosage form: Capsule, Extended release
Route: Oral
Labeler: Upsher-Smith Laboratories, LLCNDC labeler code 0832
Product type: Prescription drug
Marketing category: NDA authorized genericApplication NDA 205122
Marketing start: Jul 7, 2014
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 2C19 Inhibitors (Mechanism)Cytochrome P450 3A4 Inducers (Mechanism)Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 0832-1075_1be5841a-e872-475c-bfe9-859be4ba4001SPL ID 1be5841a-e872-475c-bfe9-859be4ba4001SPL set ID 691d276c-9cc1-4d39-828f-0f44d7ef6328RxCUI 1494769, 1812419, 1812421, 1812425, 1812427UNII 0H73WJJ391

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400832107515 followed by a unit qualifier and the quantity

Package 00832-1075-15. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 15, 2026.

Indications (excerpt from the label)

Topiramate extended-release capsules are indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older ( 1.1); adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut Syndrome in patients 2 years of age and older ( 1.2) Preventive treatment of migraine in patients 12 years of age and older ( 1.3) 1.1 Monotherapy Epilepsy Topiramate extended-release capsules are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age an…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 0832-1075

What is NDC 0832-1075?: 0832-1075 is the product NDC for Topiramate, Topiramate 150 mg/1 capsule, extended release, listed with the FDA by Upsher-Smith Laboratories, LLC. It has 3 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Topiramate.
What is the active ingredient?: Topiramate.
Who is the labeler?: Upsher-Smith Laboratories, LLC, NDC labeler code 0832. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Topiramate?: 276 other product NDCs are listed under this name. See all Topiramate NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Topiramate NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Topiramate	Topiramate 25 mg/1	Capsule, Extended releaseOral	Cranbury Pharmaceuticals, LLC	27808-325	27808-0325-01
Topiramate	Topiramate 50 mg/1	Capsule, Extended releaseOral	Cranbury Pharmaceuticals, LLC	27808-326	27808-0326-01
Topiramate	Topiramate 100 mg/1	Capsule, Extended releaseOral	Cranbury Pharmaceuticals, LLC	27808-327	27808-0327-01
Topiramate	Topiramate 150 mg/1	Capsule, Extended releaseOral	Cranbury Pharmaceuticals, LLC	27808-328	27808-0328-01
Topiramate	Topiramate 200 mg/1	Capsule, Extended releaseOral	Cranbury Pharmaceuticals, LLC	27808-329	27808-0329-01
topiramate	Topiramate 50 mg/1	Tablet, Film coatedOral	St. Mary's Medical Park Pharmacy	60760-952	60760-0952-60
topiramate	Topiramate 100 mg/1	Tablet, Film coatedOral	Coupler LLC	67046-0357	67046-0357-03
topiramate	Topiramate 100 mg/1	Tablet, Film coatedOral	Coupler LLC	67046-1691	67046-1691-03
Topiramate	Topiramate 25 mg/1	Tablet, Film coatedOral	Unit Dose Solutions, Inc.	87441-079	87441-0079-01
Topiramate	Topiramate 100 mg/1	TabletOral	Coupler LLC	67046-1688	67046-1688-03

All 277 Topiramate NDCs

Other NDCs under NDA 205122

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 205122
Product	Strength	Form · route	Labeler	Product NDC
Qudexy XRtopiramate	Topiramate 25 mg/1	Capsule, Extended releaseOral	Upsher-Smith Laboratories, LLC	0245-1071
Qudexy XRtopiramate	Topiramate 50 mg/1	Capsule, Extended releaseOral	Upsher-Smith Laboratories, LLC	0245-1072
Qudexy XRtopiramate	Topiramate 200 mg/1	Capsule, Extended releaseOral	Upsher-Smith Laboratories, LLC	0245-1073
Qudexy XRtopiramate	Topiramate 100 mg/1	Capsule, Extended releaseOral	Upsher-Smith Laboratories, LLC	0245-1074
Qudexy XRtopiramate	Topiramate 150 mg/1	Capsule, Extended releaseOral	Upsher-Smith Laboratories, LLC	0245-1075
Topiramate	Topiramate 25 mg/1	Capsule, Extended releaseOral	Upsher-Smith Laboratories, LLC	0832-1071
Topiramate	Topiramate 50 mg/1	Capsule, Extended releaseOral	Upsher-Smith Laboratories, LLC	0832-1072
Topiramate	Topiramate 200 mg/1	Capsule, Extended releaseOral	Upsher-Smith Laboratories, LLC	0832-1073
Topiramate	Topiramate 100 mg/1	Capsule, Extended releaseOral	Upsher-Smith Laboratories, LLC	0832-1074